Pricing and Reimbursement Process in Germany

This document is a guide detailing the pricing and reimbursement process for pharmaceuticals in Germany. It outlines the decentralized healthcare system where care is primarily funded through statutory and private health insurance. The guide explains that for the first six months post-launch, manufacturers can set prices freely, with most products reimbursed at 100%. It describes the role of the G-BA in issuing recommendations based on the additional benefit of new products compared to existing treatments. If a product shows additional benefit, price negotiations occur; otherwise, pricing is based on existing reference prices. The document also discusses recent changes introduced by the Medical Research Act aimed at incentivizing clinical research, including confidentiality measures for pricing and adjustments based on local research activities. The guide further elaborates on the processes involved in early benefits assessments and the importance of clinical evidence in determining reimbursement levels.